44.79

1.99% -0.91

Supernus Pharmaceuticals Inc (SUPN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SUPN? Forum Prognose

Schlusskurs vom Vortag:

$45.70

Offen:

$46.23

24-Stunden-Volumen:

744.19K

Relative Volume:

0.89

Marktkapitalisierung:

$2.51B

Einnahmen:

$665.13M

Nettoeinkommen (Verlust:

$64.50M

KGV:

39.15

EPS:

1.1442

Netto-Cashflow:

$185.87M

1W Leistung:

+0.79%

1M Leistung:

-13.18%

6M Leistung:

+34.91%

1J Leistung:

+24.00%

1-Tages-Spanne:

$44.76

$46.47

1-Wochen-Bereich:

$44.05

$46.47

52-Wochen-Spanne:

$29.16

$57.65

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Firmenname

Supernus Pharmaceuticals Inc

Sektor

Healthcare (1132)

Branche

Drug Manufacturers - Specialty & Generic (84)

Telefon

301-838-2500

Adresse

9715 KEY WEST AVENUE, ROCKVILLE, MD

Mitarbeiter

674

Twitter

@Supernus_Pharma

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

SUPN's Discussions on Twitter

Vergleichen Sie SUPN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SUPN Supernus Pharmaceuticals Inc	44.79	2.62B	665.13M	64.50M	185.87M	1.1442
ZTS Zoetis Inc	115.89	51.60B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	14.06	44.51B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.60	42.35B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	24.28	28.04B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	474.72	20.52B	3.08B	1.24B	1.07B	25.61

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-10-09	Hochstufung	Piper Sandler	Neutral → Overweight
2025-07-30	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2025-02-19	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2025-01-06	Eingeleitet	Cantor Fitzgerald	Overweight
2024-09-11	Herabstufung	Piper Sandler	Overweight → Neutral
2023-01-03	Fortgesetzt	Jefferies	Buy
2021-12-01	Fortgesetzt	Jefferies	Buy
2021-04-13	Hochstufung	Jefferies	Hold → Buy
2020-06-16	Hochstufung	Piper Sandler	Neutral → Overweight
2020-06-15	Fortgesetzt	Jefferies	Hold
2019-11-08	Herabstufung	Berenberg	Buy → Hold
2019-11-07	Herabstufung	Stifel	Buy → Hold
2019-11-06	Herabstufung	Jefferies	Buy → Hold
2018-11-12	Bestätigt	B. Riley FBR	Buy
2018-01-18	Bestätigt	B. Riley FBR, Inc.	Buy
2017-12-28	Bestätigt	B. Riley FBR, Inc.	Buy
2017-12-04	Hochstufung	Janney	Neutral → Buy
2017-11-08	Hochstufung	Stifel	Hold → Buy
2017-10-19	Eingeleitet	FBR & Co.	Buy
2017-09-19	Herabstufung	Stifel	Buy → Hold
2017-07-17	Herabstufung	Piper Jaffray	Overweight → Neutral
2017-07-14	Eingeleitet	Janney	Neutral
2017-06-01	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-07-18	Herabstufung	Northland Capital	Outperform → Market Perform
2016-07-18	Herabstufung	Piper Jaffray	Overweight → Neutral
2016-02-08	Hochstufung	Jefferies	Hold → Buy
2015-11-05	Bestätigt	Northland Capital	Outperform
2015-10-28	Eingeleitet	Northland Capital	Outperform

Alle ansehen

Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten

02:53 AM

How Supernus Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com

02:53 AM

Nov 20, 2025

Why Supernus Pharmaceuticals Inc. stock could benefit from AI revolutionQuarterly Trade Summary & Growth Focused Entry Point Reports - newser.com

Nov 20, 2025

Nov 19, 2025

Understanding the Setup: (SUPN) and Scalable Risk - news.stocktradersdaily.com

Nov 19, 2025

Advanced analytics toolkit walkthrough for Supernus Pharmaceuticals Inc.Sell Signal & Expert Approved Trade Ideas - newser.com

Nov 19, 2025

Statistical indicators supporting Supernus Pharmaceuticals Inc.’s strengthJuly 2025 Earnings & Fast Moving Stock Watchlists - newser.com

Nov 19, 2025

Measuring Supernus Pharmaceuticals Inc.’s beta against major indices2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com

Nov 19, 2025

Nov 17, 2025

Is Supernus Pharmaceuticals Inc. a candidate for recovery playJuly 2025 Price Swings & Capital Efficient Trade Techniques - newser.com

Nov 17, 2025

How Investors Are Reacting To Supernus Pharmaceuticals (SUPN) Raising 2025 Revenue Guidance Despite Net Losses - simplywall.st

Nov 17, 2025

Supernus at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com Australia

Nov 17, 2025

SUPN: Strong CNS portfolio growth, supply challenges for Onapgo, and active business development focus - TradingView

Nov 17, 2025

Nov 16, 2025

What analysts say about Supernus Pharmaceuticals Inc stockTechnical Breakout Signals & Free Powerful Profit Generation - earlytimes.in

Nov 16, 2025

Nov 15, 2025

Long term hold vs stop loss in Supernus Pharmaceuticals Inc.2025 Macro Impact & Technical Confirmation Alerts - newser.com

Nov 15, 2025

Using data models to predict Supernus Pharmaceuticals Inc. stock movementJobs Report & Weekly Momentum Stock Picks - newser.com

Nov 15, 2025

How to monitor Supernus Pharmaceuticals Inc. with trend dashboardsWeekly Investment Summary & Community Consensus Stock Picks - newser.com

Nov 15, 2025

Nov 13, 2025

Why Supernus Pharmaceuticals Inc. stock remains undervaluedEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com

Nov 13, 2025

Nov 12, 2025

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London - The Manila Times

Nov 12, 2025

Supernus (NASDAQ: SUPN) fireside chat Nov. 17 at 9:30 a.m. EST; webcast available - Stock Titan

Nov 12, 2025

Nov 11, 2025

5 Must-Read Analyst Questions From Supernus Pharmaceuticals’s Q3 Earnings Call - Yahoo Finance

Nov 11, 2025

Nov 10, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2025 Earnings Call Transcript - MSN

Nov 10, 2025

Nov 08, 2025

The Technical Signals Behind (SUPN) That Institutions Follow - news.stocktradersdaily.com

Nov 08, 2025